to successfully integrate Kineta's business or fully realize the 
anticipated synergies or other benefits expected from the Proposed 
Transaction; the ability of TuHURA to implement its plans, forecasts, 
expected financial performance and other expectations with respect to 
Kineta's business or the combined business after the completion of the 
Proposed Transaction and realize additional opportunities, develop 
customer relationships, additional products and Kineta's existing 
business; risks associated with third party contracts containing consent 
and/or other provisions that may be triggered by the Proposed 
Transaction; the potentially significant amount of any costs, fees, 
expenses, impairments or charges related to the Proposed Transaction; 
the risk of no amounts being payable under the Disposed Asset Payment 
Right as defined in the merger agreement; the potential dilution of 
TuHURA and Kineta stockholders' ownership percentage of TuHURA after the 
Proposed Transaction as compared to their ownership percentage of TuHURA 
and Kineta, as applicable, prior to the Proposed Transaction; TuHURA and 
Kineta directors and executive officers having interests in the Proposed 
Transaction that are different from, or in addition to, the interests of 
TuHURA and Kineta stockholders generally; the possibility that TuHURA's 
results of operations, cash flows and financial position after the 
Proposed Transaction may differ materially from the unaudited pro forma 
condensed combined financial information contained in the proxy 
statement/prospectus; macroeconomic conditions and geopolitical 
uncertainty in the global economy; uncertainty in the growth of the 
biopharmaceutical sector; the highly competitive industries TuHURA and 
Kineta operate in; actions by the U.S. or foreign governments, such as 
the imposition of additional export restrictions or tariffs; legislative, 
regulatory and economic developments affecting Kineta's and TuHURA's 
businesses; the evolving legal, regulatory and tax regimes under which 
Kineta and TuHURA operate; restrictions during the pendency of the 
Proposed Transaction that may impact Kineta's or TuHURA's ability to 
pursue certain business opportunities or strategic transactions; and 
unpredictability and severity of catastrophic events, including, but not 
limited to, acts of terrorism or outbreak of war or hostilities, as well 
as Kineta's and TuHURA's response to any of the aforementioned factors. 
The foregoing list of risks, uncertainties and factors is not 
exhaustive. Unlisted factors may present significant additional 
obstacles to the realization of forward-looking statements. 
      You should carefully consider the foregoing factors and the other risks 
and uncertainties that affect the businesses of TuHURA and Kineta 
described in the "Risk Factors" section of their respective Annual 
Reports on Form 10-K, Quarterly Reports on Form 10-Q and other documents 
filed by either of them from time to time with the SEC. These filings 
identify and address other important risks and uncertainties that could 
cause actual events and results to differ materially from those 
contained in the forward-looking statements. Forward-looking statements 
speak only as of the date they are made. All forward-looking statements 
by their nature address matters that involve risks and uncertainties, 
many of which are beyond TuHURA's and Kineta's control, and are not 
guarantees of future results. Readers are cautioned not to put undue 
reliance on forward-looking statements, and TuHURA and Kineta assume no 
obligation and do not intend to update or revise these forward-looking 
statements, whether as a result of new information, future events, or 
otherwise, unless required by law. Neither TuHURA nor Kineta gives any 
assurance that either TuHURA or Kineta will achieve its expectations. 
      Investor/Media Contacts: 
      TuHURA Biosciences, Inc. 
      Jenene Thomas 
      JTC Team, LLC 
      908.824.0775 
      tuhura@jtcir.com 
      Kineta, Inc. 
      Investor Relations 
      info@kineta.us 
      SOURCE: TuHURA Biosciences, Inc. 
      View the original press release on accesswire.com 
 
 

(END) Dow Jones Newswires

December 12, 2024 09:24 ET (14:24 GMT)